In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Meningioma Driver Mutations Determine Their Anatomical Site of Origin

    Final Number:
    218

    Authors:
    Murat Gunel MD; Yale-Bonn-Cologne Brain Tumor Genetics Study Group

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2016 Annual Meeting

    Introduction: Meningiomas comprise over 35% of all primary intracranial tumors, arising from the membranes surrounding the brain and spinal cord. Until recently, the genomic landscape of these tumors were poorly understood.

    Methods: We used next-generation genomic approaches to identify driver mutations in over 500 meningiomas, correlating our findings with clinical data, including their intracranial origin.

    Results: We identified driver mutations in 5 genes including NF2, TRAF7, which co-occurred with either the known oncogenic AKT1E17K mutation or with a recurrent mutation, K409Q, in the KLF4 gene and SMO activating mutations, which resulted in constitutive Sonic Hedgehog (SHH) signaling. NF2 mutant meningiomas were of fibrous or transitional histology and originated along the posterior cerebral hemispheres, the posterior and lateral part of the skull base, and along the spinal cord. In contrast, meningiomas bearing mutations in the other 4 driver genes grew almost exclusively along the midline of the skull base and anterior cerebral hemispheres. Interestingly, the growth of SMO mutant meningiomas was restricted to the midline of the anterior skull base, where Sonic Hedgehog (SHH) signaling plays a critical role in cranio-facial patterning during embryonic development.

    Conclusions: Mutually exclusive mutations in these 5 driver genes classify meningiomas into mutually-exclusive groups with distinctive clinical correlations, identifying therapeutically relevant pathways with clear implications for targeted therapies, such as AKT1 or SHH inhibition.

    Patient Care: Understanding the genomic make-up of meningiomas identify molecular targets, including AKT1 and SHH inhibitors

    Learning Objectives: Clinical correlation of the molecular landscape of meningiomas

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy